Ann Rheum Dis: Targeted therapy can improve the efficacy of multi-joint early-childhood iade arthritis

Childhood iade arthritis is one of the most common chronic inflammatory diseases in childrenThere is evidence that early and effective treatment can minimize the burden of disease in childhood and later lifeThe study hypothesized that multi-joint infant iapathic arthritis (pJIA) was better than conventional treatment with targeted therapy (T2T) to achieve clinical remission after 12 months of treatmentinclude early and active pJIA patientsThe objectives of treatment are as follows: improved activity score (JADAS) for identifiable juvenile arthritis disease after 3 months, acceptable disease at 6 months, lowest activity at 9 months, and major endpoint remission after 12 monthsInitially, the patient was treated with methotrexateFailure to reach the defined goal requires treatment changes at specified intervalsThe choice of biologics is not affected by the programmeFinally, T2T patients were compared with a group of pJIA patients with unguided therapy with a group of BIKER-recorded control steamsincluded 63 patients73%/75/77% and 48% of patients met treatment targets after 3/6/9 and 12 months, respectivelyFifty-four patients completed the treatment planCompared to the control group, more patients were able to achieve JADAS remission (48% vs 32%; OR 1.96 (1.1-3.7); p.033) and JADAS Minimum Disease Activity (JADAS-MDA) (76% vs 59%; OR 2.2 (1.1-4.4);p .028More patients treated with biologics in the T2T queue (50% vs 9% after 12 months; OR 9.8 (4.6-20.8) ;p 0.0001)The T2T concept is feasible and superior to undirected treatmentAfter 12 months, the proportion of patients who achieved JADAS-MDA and JADA remission was high About half of the patients met treatment targets without biologics